| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 3rd February 2020 | Jerry J Jasinowski | 526,316 | Grant/award etc. | $0.19 | $100,000.04 |
| 27th January 2020 | Linda F Powers | 220,000 | Open or private sale | $4.60 | $1,012,000.00 |
| 3rd June 2019 | Linda F Powers | 10,000 | Open or private purchase | $6.00 | $60,000.00 |
| 8th May 2019 | Linda F Powers | 61,667 | Open or private purchase | $9.00 | $555,003.00 |
| 28th December 2018 | Linda F Powers | 804,146 | Open or private sale | $0.17 | $136,704.82 |
| 27th December 2018 | Linda F Powers | 3,558,639 | Open or private sale | $0.17 | $604,968.63 |
Northwest Biotherapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Northwest Biotherapeutics, Inc. is a clinical stage biotechnology company. The firm engages in the development of cancer vaccines designed to treat solid tumor cancers. It also offers a platform technology for DCVax dendritic cell-based vaccines.
Ticker: NWBO
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1072379
Employees: 17
Exchange: US OTC
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $6 M (0%)
Assets, Current: $8 M (156%)
Property, Plant and Equipment, Net: $157 Th (-44%)
Other Assets, Noncurrent: $755 Th (-5%)
Assets: $15 M (63%)
Liabilities, Current: $89 M (115%)
Liabilities: $96 M (82%)
Common Stock, Value, Issued: $722 Th (17%)
Common Stock, Shares, Issued: $722 (-99%)
Additional Paid in Capital, Common Stock: $812 M (2%)
Retained Earnings (Accumulated Deficit): $895 M (6%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $2 M (91%)
Stockholders' Equity (Parent): $81 M (0%)
Liabilities and Equity: $15 M (63%)
Research and Development: $3 M (-54%)
General and Administrative Expenses: $3 M (-55%)
Operating Income/Loss: $7 M (-50%)
EPS (basic): $0.08 (0%)
EPS (diluted): $0.08 (0%)
News
Top Stocks To Buy In March
8th March 2021
